Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Pulmonary, Neuropathic Pain, and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AGTR2 drug discovery, designed to overcome critical assay challenges: AT1/AT2 selectivity, GPCR conformation integrity, and cross-species translation.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | AGTR2 Lentivirus Premade Particles (Full-length ORF) for stable cell line generation. Preserves native 7TM conformation for functional GPCR assays (calcium flux, cAMP, β-arrestin). | View AGTR2 Products |
| Antigen | AGTR2 HEK293 Membrane Preparation (Full-length) or Nanodiscs. Sequence Verified, High Purity (>95%), Endotoxin <1EU/µg. Suitable for radioligand binding, ELISA, and immunization. | View AGTR2 Products |
| Benchmark Ab | Anti-AGTR2 Recombinant Antibody (Positive Control). Sequence Verified. For assay development, FACS, and specificity confirmation. | View AGTR2 Products |
| Validator | AGTR2 siRNA Set (3 unique sequences). For knockdown verification and specificity controls in cell-based functional assays. | View AGTR2 Products |
| Species Orthologs | AGTR2 Cynomolgus / Mouse Lentivirus and Membrane Preparations. For preclinical translation and cross-species selectivity assessment. | View AGTR2 Products |
| Related Target A | AGTR1 (AT1R) Lentivirus / Membrane Prep. Essential for counter-screening; highly homologous opposing-pathway receptor. | View AGTR1 Products |
| Related Target B | ACE2 Recombinant Protein (Active Domain). Key counter-regulatory enzyme in the RAS protective axis; synergistic target for fibrotic and cardiovascular studies. | View ACE2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| AT1/AT2 Subtype Selectivity | AGTR1 vs AGTR2 stable cell lines with Sequence Verified ORFs; >95% transduction efficiency confirmed by flow cytometry. Parallel counter-screening available. |
| Functional GPCR Conformation Integrity | Lentivirus-encoded AGTR2 preserves native glycosylation and 7-TM architecture. HEK293 expression ensures proper post-translational modification. |
| Lack of Reliable Controls | Recombinant benchmark antibodies and validated siRNA included for rigorous specificity checks. |
| False Positives / Off-target Binding | AGTR2-specific siRNA for target validation; AGTR1 homolog proteins for strict counter-screening. |
| Cross-species Translation | Human/Cynomolgus/Mouse ortholog cell lines with >98% sequence homology for preclinical safety evaluation. |
Live AGTR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AGTR2 therapeutics is intensifying, with major players shifting focus from traditional ACE/ARB strategies to direct AGTR2 modulation. Selective agonists such as Compound 21 (Vicore Pharma) are advancing through Phase II for neuropathic pain and idiopathic pulmonary fibrosis, validating the paradigm of AT2R-mediated tissue protection. While next-generation R&D is targeting tissue-specific delivery and biased signaling profiles to uncouple therapeutic efficacy from classical RAS side effects, emerging biotechs are also exploring highly selective monoclonal antibodies and novel delivery systems to bypass early small-molecule toxicity issues (e.g., EMA401 hepatotoxicity).
The therapeutic landscape is pivoting toward high-selectivity small molecules, peptide mimetics, and biased ligands. Unlike AT1R, which drives vasoconstriction and inflammation, AGTR2 activation promotes vasodilation, anti-fibrotic signaling, and neuronal regeneration—opening indications beyond hypertension into organ protection and neuroregeneration. Over the next 3–5 years, we anticipate increased use of combination strategies (AGTR2 agonists with SGLT2 inhibitors or ARNI therapies in HFpEF) and a strong emphasis on species cross-reactivity validation for regulatory packages. Genetic polymorphisms (e.g., 1675G>A) may influence ligand binding and clinical response, warranting consideration in precision medicine approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Vicore Pharma, Novartis | Pulmonary Arterial Hypertension, IPF, Neuropathic Pain | Gi-coupled cAMP / GTPγS Assay (Need stable cell lines via Lentivirus) |
| Small Molecule Antagonist | Spinifex Pharmaceuticals (Novartis) | Neuropathic Pain (post-herpetic neuralgia) | Radioligand Displacement (Need high-purity membrane preps) |
| Radioligand / Imaging Tracer | Molecular Imaging Consortiums | Cardiac Fibrosis, Oncology Imaging | Saturation Binding (Need sequence-verified full-length membrane antigen) |
| Peptide Agonist (C21 analogs) | University research consortiums | Heart Failure, Diabetic Nephropathy | Internalization Assay (Endosomal trafficking validation) |
| Biased Ligands | AstraZeneca, Merck | Anti-fibrotic (NASH/ILD) | Arrestin vs G-protein pathway bias assays (Need high-expression stable pools) |
| Monoclonal Antibody | Emerging Biotechs | Fibrosis / Inflammation | Conformational Binding (Need high-purity membrane preps) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Affinity & Selectivity: AGTR2 drugs must achieve >1000-fold selectivity over AGTR1 to avoid off-target vasoconstriction and blood pressure elevation. Parallel counter-screening using AGTR1 stable cell lines is mandatory.
- Mechanism Characterization: Agonists require GI-coupled cAMP inhibition assays; antagonists require complete blockade of Ang II-induced signaling. Biased ligands necessitate dual-readout platforms (G-protein vs β-arrestin).
- Delivery & Exposure: For neuropathic pain, peripheral restriction with minimal CNS penetration is preferred; for PAH/IPF, systemic exposure and lung distribution are critical. Early assessment of stability and viscosity supports formulation decisions.
- Safety Assessment: Beyond AGTR1 selectivity, evaluate potential interference with AT1R-AT2R heterodimers. Hepatotoxicity screening (as seen with EMA401) is essential for oral small molecules.
- Species Cross-Reactivity: Preclinical safety studies require human, cynomolgus, and rodent ortholog cell lines to validate binding and functional activity.
Recommended Screening Assays
- Radioligand Competition Binding: Use high-purity AGTR2 membrane preparations for 125I-Ang II displacement to determine precise Ki values.
- Functional Second Messenger Assays: Lentivirus-based stable cell lines for cAMP inhibition (HTRF/LANCE) and calcium flux (FLIPR) to confirm agonism/antagonism.
- Biased Signaling Profiling: BRET-based assays measuring Gαq activation and β-arrestin2 recruitment; calculate bias factor for candidate ranking.
- Cross-Species Counter-Screening: Parallel testing on human, cynomolgus, and mouse AGTR2 cell lines to ensure translational relevance.
- Target Validation: Use AGTR2 siRNA knockdown in stable cell lines to confirm on-target activity.
- Selectivity Panel: AGTR1 homologous cells for parallel binding and functional assays; ensure >1000-fold selectivity window.
TarMart Solution
TarMart follows a "cell-line-first" strategy for AGTR2 GPCR drug discovery. We provide HEK293-expressed full-length AGTR2 membrane preparations (endotoxin <1 EU/µg, sequence verified, purity >95%) that retain native glycosylation and transmembrane conformation. Our lentivirus premade particles enable rapid construction of stable cell lines (within 1–2 weeks) for AGTR2 and AGTR1, supporting calcium flux, flow cytometry, and GTPγS functional assays. Additionally, we offer AGTR2 siRNA for target validation and ACE2 recombinant protein for full RAS pathway studies. This comprehensive toolkit covers the entire workflow from hit validation to lead optimization.
Related Targets for Cross-Selling
- AGTR1 (AT1R) : Mandatory counter-screening target. Required for any AGTR2 project to exclude off-target activity. Essential for selectivity profiling.
- ACE2: Core synergistic partner in the RAS protective axis (ACE2/Ang-(1-7)/Mas). Often studied together with AGTR2 in fibrosis, lung injury, and cardiovascular indications.
- MAS1: GPCR receptor for Ang-(1-7), forming a protective heterodimer with AGTR2. Forward-looking target for combination therapy and pathway research.